MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145958 | Name: DM-4103

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DM-4103 is a plant growth regulator used primarily to enhance the growth and development of crops, particularly in rice and other cereals. It works by influencing the plant's hormonal balance, particularly by modulating the activity of gibberellins, which are responsible for regulating stem elongation and overall growth. This regulation helps to promote stronger, more resilient plants, preventing issues like lodging and improving crop yield. DM-4103 is commonly applied to optimize plant structure, ensuring healthier crops and better resistance to environmental stresses.

Chemical Structure

DM-4103
DM-4103
CAS#1346599-56-1

Theoretical Analysis

MedKoo Cat#: 145958

Name: DM-4103

CAS#: 1346599-56-1

Chemical Formula: C26H23ClN2O5

Exact Mass: 478.1300

Molecular Weight: 478.93

Elemental Analysis: C, 65.21; H, 4.84; Cl, 7.40; N, 5.85; O, 16.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
DM-4103; DM 4103; DM4103;
IUPAC/Chemical Name
4-(5-chloro-2-(2-methyl-4-(2-methylbenzamido)benzamido)phenyl)-4-oxobutanoic acid
InChi Key
PRTSBHBGYFDAAS-UHFFFAOYSA-N
InChi Code
1S/C26H23ClN2O5/c1-15-5-3-4-6-19(15)25(33)28-18-8-9-20(16(2)13-18)26(34)29-22-10-7-17(27)14-21(22)23(30)11-12-24(31)32/h3-10,13-14H,11-12H2,1-2H3,(H,28,33)(H,29,34)(H,31,32)
SMILES Code
CC1=CC=CC=C1C(=O)NC2=CC=C(C(=O)NC3=CC=C(Cl)C=C3C(=O)CCC(O)=O)C(C)=C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 478.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ma Y, Yu M, Wang H. Development, validation and application of a UPLC-MS/MS method for simultaneous quantification of OPC-61815 and its metabolites tolvaptan, DM-4103 and DM-4107 in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Jul 15;1242:124213. doi: 10.1016/j.jchromb.2024.124213. Epub 2024 Jun 19. PMID: 38909567. 2: Beaudoin JJ, Brock WJ, Watkins PB, Brouwer KLR. Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity. Clin Pharmacol Ther. 2021 Feb;109(2):433-442. doi: 10.1002/cpt.2007. Epub 2020 Sep 8. PMID: 32748396; PMCID: PMC7854848. 3: Shoaf SE, Bricmont P, Repella Gordon J. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters. Clin Transl Sci. 2021 Jul;14(4):1535-1542. doi: 10.1111/cts.13017. Epub 2021 Apr 9. PMID: 33742787; PMCID: PMC8301576. 4: Beaudoin JJ, Bezençon J, Cao Y, Mizuno K, Roth SE, Brock WJ, Brouwer KLR. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. Drug Metab Dispos. 2019 Feb;47(2):155-163. doi: 10.1124/dmd.118.083907. Epub 2018 Nov 30. Erratum in: Drug Metab Dispos. 2019 Mar;47(3):328. doi: 10.1124/dmd.115.083907err. PMID: 30504136; PMCID: PMC6338823. 5: Hoshikawa K, Naito T, Saotome M, Maekawa Y, Kawakami J. Validated liquid chromatography coupled to tandem mass spectrometry method for simultaneous quantitation of tolvaptan and its five major metabolites in human plasma. Ann Clin Biochem. 2019 May;56(3):387-396. doi: 10.1177/0004563219827045. Epub 2019 Mar 4. PMID: 30832482. 6: Hammond S, Gibson A, Jaruthamsophon K, Roth S, Mosedale M, Naisbitt DJ. Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicol Sci. 2021 Jan 6;179(1):95-107. doi: 10.1093/toxsci/kfaa157. PMID: 33078835. 7: Lu Y, Slizgi JR, Brouwer KR, Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL. Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes. Drug Metab Dispos. 2016 Jun;44(6):867–70. doi: 10.1124/dmd.115.067629. Epub 2016 Mar 24. PMID: 27013400; PMCID: PMC4885486. 8: Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, Brock WJ, Brouwer KL. Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury? Toxicol Sci. 2016 Jan;149(1):237-50. doi: 10.1093/toxsci/kfv231. Epub 2015 Oct 26. PMID: 26507107; PMCID: PMC6169477. 9: Liu H, Wang Y, Liu T, Chen Y, Zheng X, Liu M, Zhao Q, Zeng M, Jiang J, Mao Y, Hu P. Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis. Front Pharmacol. 2024 Jan 26;15:1324299. doi: 10.3389/fphar.2024.1324299. PMID: 38344178; PMCID: PMC10853469. 10: Jiang J, Tian L, Huang Y, Yan Y, Li Y. A rapid and sensitive LC-MS/MS-ESI method for the determination of tolvaptan and its two main metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:158-64. doi: 10.1016/j.jchromb.2016.03.032. Epub 2016 May 6. PMID: 27288933. 11: Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, Grammatopoulos TN, Stiles L, Siler SQ, Howell BA, Mosedale M, Watkins PB, Shoda LK. Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicol Sci. 2017 Jan;155(1):61-74. doi: 10.1093/toxsci/kfw193. Epub 2016 Sep 21. PMID: 27655350; PMCID: PMC5216653.